HLHanyan Liu

Hanyan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hanyan Liu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Shaoquan Zhan

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou 510150

    4 shared publications
  • Jianqiao Liu

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou

    3 shared publications
  • Chunyan Wang

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou

    2 shared publications
  • Geng An

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China

    2 shared publications
  • Hongzi Du

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou

    2 shared publications
  • Jiayu Gan

    Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou

    2 shared publications

Latest Publications

  • Open Access

    The dynamic landscape and conserved regulation of the m6Am and m6A methylomes during the human and mouse oocyte-to-embryo transition

    by Ruibao Su, Zongchang Du, Sen Li, Hanyan Liu, Di Gao, Shaoquan Zhan, Chao Li, Tie-Gang Meng, Lei-Ning Chen, Li-Hua Fan, et al.

    N 6-methyladenosine (m6A) and N6, 2′-O-dimethyladenosine (m6Am) are two RNA modifications that play essential roles in diverse RNA metabolic processes and functions. Despite their importance, the dynamic landscapes and regulatory patterns of m6A and m6Am during the oocyte-to-embryo transition (OET) in humans and mice remain elusive. Here, we developed a highly sensitive method, MeLACE-seq, to profile the m6A and m6Am landscapes across human and mouse oocytes to pre-implantation embryos. We reveal that the zygotic genome activation (ZGA) stage serves as a regulatory node where both the m6A and m6Am methylomes undergo dramatic, species-specific changes. Moreover, transcripts marked by m6A and m6Am are generally expressed and translated at higher levels than unmarked transcripts. Additionally, we discovered that m6A modifications are extensively deposited on human retrotransposon RNAs. These m6A marks exhibit a functional shift, showing a positive correlation with elevated retrotransposon RNA levels in pre-ZGA embryos, but a negative correlation with their expression around the ZGA stage. Together, these findings reveal conserved and species-specific regulatory patterns of the epitranscriptome during human and mouse OETs, providing new insights into the roles of RNA modifications in embryogenesis.


  • Type 2 diabetes mellitus increases surgical sperm retrieval but preserves semen quality and cumulative live birth rate

    by Hanyan Liu, Feixue Han, Xiaomin Li, Tianwen Peng, Zhicong Chen, Man Wu, Jiajing Lin, Hongfei Ke, Zhiying Huang, Zhijie Li, et al.


  • Open Access

    Comparison of fresh testicular sperm aspiration and use of either thawed pre-frozen sperm or oocyte freezing: impact on cumulative live birth rates for couples experiencing ejaculation failure

    by Shaoquan Zhan, Geng An, Jiayu Gan, Hongzi Du, Xin Fu, Chunyan Wang, Yuling Mao, Xiangjin Kang, Jianqiao Liu, Hanyan Liu

    STUDY QUESTION: Is there a difference in the cumulative live birth rate (CLBR) after fresh testicular sperm aspiration (TESA) compared with the use of either pre-frozen sperm or oocyte freezing for couples experiencing ejaculation failure on the day of oocyte retrieval? SUMMARY ANSWER: After adjusting for confounding factors, the use of pre-frozen sperm or the freezing and thawing of oocytes appeared to be as effective as TESA in achieving CLBRs for couples experiencing temporary ejaculation failure. WHAT IS KNOWN ALREADY: Male patients may be concerned about experiencing temporary ejaculation failure on the day of their partner’s oocyte retrieval, in which case they may choose surgical sperm retrieval, oocyte freezing on the day, or have their sperm frozen in advance. However, the clinical efficacy of these three options has not yet been evaluated. STUDY DESIGN, SIZE, DURATION: A retrospective data analysis was conducted on 65 178 oocyte retrieval cycles at a university-affiliated IVF center from January 2012 to May 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: The overall characteristics, completed cycle characteristics, and clinical outcomes were analyzed among couples with ejaculation failure who underwent three distinct clinical interventions, with those receiving TESA serving as the control group. The primary outcome measure was the CLBR, and the secondary outcome measures were the clinical pregnancy rate (CPR) and live birth rate (LBR) per embryo transfer. A robust (modified) Poisson regression model was used to evaluate the association between the three clinical options for ejaculation failure and CLBRs. MAIN RESULTS AND ROLE OF CHANCE: Of the eligible oocyte retrieval cycles, 756 cycles (1.2%) experienced ejaculation failure, with 640 cycles completing treatment. These treatments included 325 cycles using TESA, 227 cycles utilizing pre-frozen sperm, and 88 cycles involving frozen–thawed oocytes. The CLBRs for the TESA, thawed-sperm and thawed-oocyte groups were 36.9%, 48.9%, and 34.1%, respectively, showing a statistically significant difference (P = 0.007). Specifically, the thawed-sperm group demonstrated a significantly higher CLBR compared to the TESA group, while no significant difference was observed between the TESA and thawed-oocyte groups. Similarly, the CPRs and LBRs per embryo transfer for the three groups were 37.4%, 50.0%, and 41.8%, respectively (P = 0.005), and 29.9%, 39.6%, and 33.0%, respectively (P = 0.030). Again, the thawed-sperm group showed a significantly higher CPR and a significantly higher LBR, but no significant differences for the thawed-oocyte group, compared to the TESA group. Notably, the significant differences in both CLBR and LBR emerged after the second embryo transfer. However, after adjusting for multiple factors, including female age at oocyte retrieval, type and duration of infertility, female body mass index, number of previous IVF cycles, ovarian stimulation protocol, endometrial thickness on the last ultrasound, insemination method, number of oocytes retrieved, number of fertilized oocytes, and number of usable embryos on Day 3, the analysis revealed no significant association between CLBR and the use of pre-frozen sperm (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.81–1.44) or thawed oocytes (RR 1.01, 95% CI 0.76–1.33), compared with TESA. LIMITATIONS, REASONS FOR CAUTION: Given that the study is retrospective and the sample size is too small, particularly concerning the use of thawed oocytes, we acknowledge that the data present here is only suggestive and refers to an association that warrants cautious interpretation. Therefore, further research in the form of prospective studies as well as randomized controlled trials is needed to provide a definitive answer to the research question. WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that using pre-frozen sperm or frozen-thawed oocytes can offer comparable CLBRs to TESA for cases of temporary ejaculation failure, providing clinical alternatives that may reduce the logistical challenges in ART cycles. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Nature Science Foundation of China (grant nos. 82101672, 82171589), the National Key Research and Development Program of China (grant nos. 2022YFC2702504, 2019YFE0109500), the Basic and Applied Basic Research Foundation of Guangdong Province (grant no. 2021A1515010774), and the Guangzhou Municipal Science and Technology Project (grant nos. 202102010075, 2023A4J0578). The authors declare that they have no conflict of interest in relation to the data in this paper. TRIAL REGISTRATION NUMBER: N/A


  • Open Access

    Vitrification preservation of good-quality blastocysts for more than 5 years reduces implantation and live birth rates

    by Shaoquan Zhan, Chenxing Lin, Qiwang Lin, Jiayu Gan, Chunyan Wang, Yang Luo, Jianqiao Liu, Hongzi Du, Hanyan Liu

    STUDY QUESTION: Does vitrification cryopreservation of embryos for more than 5 years affect the pregnancy outcomes after frozen embryo transfer (FET)? SUMMARY ANSWER: Vitrification cryopreservation of good-quality blastocysts for more than 5 years is associated with a decrease in the implantation rate (IR) and live birth rate (LBR). WHAT IS KNOWN ALREADY: Previous studies have predominantly focused on embryos cryopreserved for relatively short durations (less than 5 years), yet the impact of extended cryopreservation duration on pregnancy outcomes remains a controversial issue. There is a relative scarcity of data regarding the efficacy and safety of storing embryos for 5 years or longer. STUDY DESIGN, SIZE, DURATION: This retrospective study involved 36 665 eligible vitrified-thawed embryo transfer cycles from 1 January 2016 to 31 December 2022, at a single fertility center in China. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were divided into three groups according to embryo storage time: Group 1 consisted of 31 565 cycles, with storage time of 0–2 years; Group 2 consisted of 4458 cycles, with a storage time of 2–5 years; and Group 3 included 642 cycles, with storage time exceeding 5 years. The main outcome measures were IR and LBR. Secondary outcome variables included rates of biochemical pregnancy, multiple pregnancy, ectopic pregnancy, and miscarriage, as well as neonatal outcomes. Reproductive outcomes were analyzed as binary variables. Multivariate logistic regression analysis was used to explore the effect of preservation time on pregnancy outcomes after correcting for confounding factors. In addition, we also assessed neonatal outcomes, such as large for gestational age (LGA) and small for gestational age (SGA). MAIN RESULTS AND THE ROLE OF CHANCE: IRs in the three groups (0–2, 2–5, and >5 years) were 37.37%, 39.03%, and 35.78%, respectively (P = 0.017), and LBRs in the three groups were 37.29%, 39.09%, and 34.91%, respectively (P = 0.028). After adjustment for potential confounding factors, compared with the 0–2 years storage group, prolonged embryo vitrification preservation time (2–5 years or >5 years) did not affect secondary outcomes such as rates of biochemical pregnancy, multiple pregnancy, ectopic pregnancy, and miscarriage (P > 0.05). But cryopreservation of embryos for more than 5 years reduced the IR (adjusted odds ratio (aOR) 0.82, 95% CI 0.69–0.97, P = 0.020) and LBR (aOR 0.76, 95% CI 0.64–0.91, P = 0.002). Multivariate stratified analysis also showed that prolonging the cryopreservation time of blastocysts (>5 years) reduced the IR (aOR 0.78, 95% CI 0.62–0.98, P = 0.033) and LBR (aOR 0.68, 95% CI 0.53–0.87, P = 0.002). However, no effect on cleavage embryos was observed (P > 0.05). We further conducted stratified analyses based on the number and quality of frozen blastocysts transferred, and the results showed that the FET results after transfers of good-quality blastocysts in the >5 years storage group were negatively affected. However, the storage time of non-good-quality blastocysts was not significantly associated with pregnancy outcomes. Regarding the neonatal outcomes (of singletons), embryo vitrification preservation time had no effect on preterm birth rates, fetal birth weight, or neonatal sex ratios. However, as the storage time increased, rates of SGA (5.60%, 4.10%, and 1.18%) decreased, while rates of LGA (5.22%, 6.75%, and 9.47%) increased (P < 0.05). After adjusting for confounding factors, the increase in LGA and the decrease in SGA were significantly correlated with the duration of storage time. LIMITATIONS, REASONS FOR CAUTION: This was a retrospective study using data from a single fertility center, even though the data had been adjusted, our findings still need to be validated in further studies. WIDER IMPLICATIONS OF THE FINDINGS: With the full implementation of the two-child policy in China, there may be more patients whose embryos have been frozen for a longer time in the future. Patients should be aware that the IR and LBR of blastocysts are negatively affected when the cryopreservation time is longer than 5 years. Couples may therefore consider shortening the time until FET treatment. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Nature Science Foundation of China (No. 82101672), Science and Technology Projects in Guangzhou (No. 2024A03J0180), General Guidance Program for Western Medicine of Guangzhou Municipal Health Commission (No. 20231A011096), and the Medical Key Discipline of Guangzhou (2021–2023). None of the authors have any conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.


  • Open Access

    Inactivated Covid-19 vaccine did not undermine live birth and neonatal outcomes of women with frozen-thawed embryo transfer

    by Mingzhu Cao, Yixuan Wu, Yanshan Lin, Zijin Xu, Zhu Liang, Qing Huang, Sichen Li, Hanyan Liu, Chunyan An, Yiqun Luo, et al.

    Does inoculation with inactivated vaccines against coronavirus disease 2019 (Covid-19) before frozen-thawed embryo transfer (FET) affect live birth and neonatal outcomes? Inactivated Covid-19 vaccines did not undermine live birth and neonatal outcomes of women planning for FET. Accumulating reports are now available indicating the safe use of mRNA vaccines against Covid-19 in pregnant and lactating women, and a few reports indicate that they are not associated with adverse effects on ovarian stimulation or early pregnancy outcomes following IVF. Evidence about the safety of inactivated Covid-19 vaccines is very limited. This is a retrospective cohort analysis from Reproductive Medical Center of a tertiary teaching hospital. Clinical records and vaccination record of 2574 couples with embryos transferred between 1 March 2021 and 30 September 2021 were screened for eligibility of this study. Clinical and vaccination data of infertile couples planning for FET were screened for eligibility of the study. The reproductive and neonatal outcomes of FET women inoculated with inactivated Covid-19 vaccines or not were compared. The primary outcomes were live birth rate per embryo transfer cycle and newborns’ birth height and weight. Secondary outcomes included rates of ongoing pregnancy, clinical pregnancy, biochemical pregnancy and spontaneous miscarriage. Multivariate logistical regression and propensity score matching (PSM) analyses were performed to minimize the influence of confounding factors. Subgroup analyses, including single dose versus double dose of the vaccines and the time intervals between the first vaccination and embryo transfer, were also performed. Vaccinated women have comparable live birth rates (43.6% versus 45.0% before PSM, P = 0.590; and 42.9% versus 43.9% after PSM, P = 0.688), ongoing pregnancy rates (48.2% versus 48.1% before PSM, P = 0.980; and 52.2% versus 52.7% after PSM, P = 0.875) and clinical pregnancy rate (55.0% versus 54.8% before PSM, P = 0.928; and 54.7% versus 54.2% after PSM, P = 0.868) when compared with unvaccinated counterparts. The newborns’ birth length (50.0 ± 1.6 versus 49.0 ± 2.9 cm before PSM, P = 0.116; and 49.9 ± 1.7 versus 49.3 ± 2.6 cm after PSM, P = 0.141) and birth weight (3111.2 ± 349.9 versus 3030.3 ± 588.5 g before PSM, P = 0.544; and 3053.8 ± 372.5 versus 3039.2 ± 496.8 g after PSM, P = 0.347) were all similar between the two groups. Neither single dose nor double dose of vaccines, as well as different intervals between vaccination and embryo transfer showed any significant impacts on reproductive and neonatal outcomes. The main findings might be limited by retrospective design. Besides, inoculations of triple dose of Covid-19 vaccines were not available by the time of data collection, thus the results cannot reflect the safe use of triple dose of inactivated Covid-19 vaccines. Finally, history of Covid-19 infection was based on patients’ self-report rather than objective laboratory tests. Eligible individuals of inactivated vaccines against Covid-19 should not postpone vaccination plan because of their embryo transfer schedule, or vice versa. This study was supported by the Medical Key Discipline of Guangzhou (2021–2023). All authors had nothing to disclose. N/A.


  • Open Access

    Kallistatin in follicular fluid of women with endometriosis and its correlation with IVF outcome

    by Yuling Mao, Shaoquan Zhan, JingDa Qiao, Lei Li, Hanyan Liu, Rui Chen

    Endometriosis (EM) affects 10% women of reproductive age and alters fertility. Its management is still debated notably the timing of surgery and ART in infertility. Kallistatin (KS) is an endogenou... 背景:子宫内膜异位症(EM)影响10%的育龄妇女并改变其生育能力。它的管理仍然存在争议, 尤其是不孕症的手术和ART的时机。人源性激肽释放酶结合蛋白(KS)是一种内源性蛋白, 调节差异信号通路和生物学功能。然而, EM的功能和潜在的分子机制及其与体外受精(IVF)结局的相关性尚未确定。本研究旨在探讨进行体外受精-胚胎移植 (IVF-ET)的子宫内膜异位症(EM)与非EM患者卵泡液(FF)中K...

  • Open Access

    Poor-quality embryos compared with available embryos at cleavage stage have similar outcomes in vitrified-thawed single blastocyst transfer

    by Hanyan Liu, Shaoquan Zhan, Xiaolin Long, Lei Li, Hongzi Du, Xiangjin Kang, Jianqiao Liu

    Background It was known that in patients with good prognosis, day 5 good-quality blastocysts formed by available cleavage embryos (AEs) or poor-quality cleavage embryos (PQEs) did not affect clinical outcomes. However, the clinical outcomes of day 5/6 expanded blastocysts cultured in patients who faced with PQEs was unclear. Methods Retrospective cohort study was conducted among women aged ≤ 38 who underwent vitrified-warmed single blastocyst transfers (SBTs) which originated from AEs (n = 382), PQEs with AEs (n = 99), or only PQEs without AEs (n = 101). Results The PQEs compared to the AEs showed lower CPR (38.38% in PQEs with AEs; 36.63% in PQEs without AEs; versus 57.07% in AEs) and lower LBR (28.28%; 29.70%; versus 44.50%), but there was no statistical difference in CPR (adjusted OR 0.78, 95% CI 0.46–1.31; adjusted OR 0.82, 95% CI 0.47–1.42) and LBR (adjusted OR 0.91, 95% CI 0.53–1.59; adjusted OR 0.94, 95% CI 0.50–1.78) after controlling for confounding variables. Better outcomes were associated with thicker endometrial thickness (CPR: adjusted OR 1.18, 95% CI 1.05–1.33; LBR: adjusted OR: 1.16, 95% CI 1.03–1.30) and blastocyst expansion on day 5 (CPR: adjusted OR 2.52 95% CI 1.62–3.94; LBR: adjusted OR: 2.28, 95% CI 1.43–3.65). ICM score C (CPR: adjusted OR 0.08, 95% CI 0.01–0.67; LBR: adjusted OR: 0.10, 95% CI 0.01–0.76) were associated with worse outcomes. Conclusions Once the blastocyst was available, endometrial thickness, ICM grade, and the day of blastocyst expansion were the factors affecting the outcome, while the quality of cleavage embryos (PQEs or AEs) had no effect on subsequent clinical outcomes.